Share this article Share this article SAN FRANCISCO, March 4, 2021 /PRNewswire/ -- Nalu Bio, Inc. today announced a collaboration with Ken Mackie, M.D., Chair and Distinguished Professor at Indiana University's Gill Center for Biomolecular Science, to evaluate how the potency and efficacy of the company's proprietary synthetic cannabinoids - specifically their close-to-market cannabidiol (CBD) - may enable the development of effective non-opioid pain management. Nalu Bio. Learning from nature, delivering through chemistry. "I am excited to bring a new category of chemistry-derived cannabinoids to patients worldwide" -Prof. Mackie Nalu Bio has developed a proprietary chemistry platform that enables highly efficient commercial production of organically synthesized cannabinoids. The collaboration with Prof. Mackie aims to demonstrate that synthetic CBD has the same potency and efficacy as plant-derived CBD.